Aflibercept in Patients With Pigment Epithelial Detachments (PED)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to AMD
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
In total 20 eyes/patients are treated and observed after inclusion diagnosis and informed consent over a period about 1 year.
Patients with vascular PED due to AMD
Male or female patients with the age > 50 years
Angiographic and via OCT ensured PED ≥ 200 µm in the eye for treatment
Written informed consent
Best corrected visual acuity (ETDRS-Visus): 24 - 73 letters within
Patients that do not fulfill the a. m. inclusion criteria
Patients which have been treated with steroids or with verteporfin via photodynamic therapy or focal lasercoagulation treatment until 3 months before,
Anti VEGF therapy until 1 month before screening
Patients with other retinal vascular diseases including diabetic rethinopathia or retinal vein occlusion
Other ocular operative procedurs 3 months before Screening
Anamnesis of non controlled glaucoma
Active or intraocular Inflammation or Inflammation of ocular adnexa
Subfoveal fibrosis within study eye
Larger surgical interventions 1 month before Screening
Anamnesis of serious cardiovascular diseases or stroke 6 months before srceening
Allergy of components of the study medication
Patients which might be not compliant
Patients participating at another clinical trial at the same time
Pregnancy, breastfeeding, women in child-bearing years without using a safe contraception method
Chronical alcohol- or drug abuse within the last year
lack of capacity and/or knowledge of German language